Who Exports Guaifenesin from India — 151 Suppliers Behind a $26.7M Market
India's guaifenesin export market is supplied by 151 active exporters who collectively shipped $26.7M across 1,050 shipments. GRANULES INDIA LIMITED leads with a 35.4% market share, followed by ELYSIUM PHARMACEUTICALS LTD and SUN PHARMACEUTICAL INDUSTRIES LIMITED. The top 5 suppliers together control 62.8% of total export value, reflecting a concentrated market structure.
Top Guaifenesin Exporters from India — Ranked by Export Value
GRANULES INDIA LIMITED is the leading guaifenesin exporter from India, holding a 35.4% share of the $26.7M market across 1,050 shipments from 151 exporters. The top 5 suppliers — GRANULES INDIA LIMITED, ELYSIUM PHARMACEUTICALS LTD, SUN PHARMACEUTICAL INDUSTRIES LIMITED, BRAWN LABORATORIES LIMITED, AGIO PHARMACEUTICALS LIMITED — collectively control 62.8% of total export value, indicating a moderately concentrated market. Individual shares are: GRANULES INDIA LIMITED (35.4%), ELYSIUM PHARMACEUTICALS LTD (18.1%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (3.4%), BRAWN LABORATORIES LIMITED (3.0%), AGIO PHARMACEUTICALS LIMITED (2.9%).
Top Guaifenesin Exporters from India
Ranked by export value · 151 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | GRANULES INDIA LIMITED GUAIFENESIN EXTENDED RELEASE TABLETS 600MGGUAIFENESIN EXTENDED RELEASE TABLETS 1200MG-14'SGUAIFENESIN EXTENDED RELEASE TABLETS 1200MG | $9.4M | 2 | 35.4% |
| 2 | ELYSIUM PHARMACEUTICALS LTD GUAIFENESIN EXTENDED RELEASE TABLETS 600MGGUAIFENESIN EXTENDED RELEASE TABLETS 1200MG-14'SGUAIFENESIN EXTENDED RELEASE TABLETS 1200MG | $4.8M | 1 | 18.1% |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED GUAIFENESIN EXTENDED RELEASE TABLETS 600MGGUAIFENESIN EXTENDED RELEASE TABLETS 1200MG-14'SGUAIFENESIN EXTENDED RELEASE TABLETS 1200MG | $899.7K | 1 | 3.4% |
| 4 | BRAWN LABORATORIES LIMITED DOLOFLU (PARACETAMOL 500MG - GUAIFENESIN | $793.2K | 2 | 3.0% |
| 5 | AGIO PHARMACEUTICALS LIMITED KOFASMA SYRUP 200 MLKOFASMA SYRUP 100 ML | $781.2K | 3 | 2.9% |
| 6 | LINCOLN PHARMACEUTICALS LTD GUAIFENESIN WITH BROMHEXINE HYDROCHLORIDDOLOFLU (PARACETAMOL 500MG - GUAIFENESIN | $658.6K | 2 | 2.5% |
| 7 | EMCURE PHARMACEUTICALS LIMITED GUAIFENESIN WITH BROMHEXINE HYDROCHLORIDPHARMACEUTICALS- MUCOROL-S LIQUID 100ML | $645.9K | 11 | 2.4% |
| 8 | GLENMARK PHARMACEUTICALS LIMITED GUAIFENESIN WITH BROMHEXINE HYDROCHLORIDASCORIL TABLETS KH 10X1X10'S | $594.8K | 7 | 2.2% |
| 9 | MARKSANS PHARMA LIMITED GUAIFENESIN EXTENDED RELEASE TABLETS 600MGGUAIFENESIN EXTENDED RELEASE TABLETS 1200MG-14'SGUAIFENESIN EXTENDED RELEASE TABLETS 1200MG | $576.5K | 3 | 2.2% |
| 10 | DR.REDDY'S LABORATORIES LTD GUAIFENESIN EXTENDED RELEASE TABLETS 600MGGUAIFENESIN EXTENDED RELEASE TABLETS 1200MG-14'SGUAIFENESIN EXTENDED RELEASE TABLETS 1200MG | $572.2K | 1 | 2.1% |
| 11 | ELYSIUM PHARMACEUTICALS LIMITED GUAIFENESIN EXTENDED RELEASE TABLETS 600MGGUAIFENESIN EXTENDED RELEASE TABLETS 1200MG-14'SGUAIFENESIN EXTENDED RELEASE TABLETS 1200MG | $566.3K | 1 | 2.1% |
| 12 | CADILA PHARMACEUTICALS LIMITED MUCOSIL BR SYRUP 1 X 100MLMUCOSIL AM SYRUP 1X100ML | $419.5K | 4 | 1.6% |
| 13 | CHANDRA BHAGAT PHARMA LIMITED GUAIFENESIN ORAL SOLUTION USP 100MG/5MLGUAIFENESIN ORAL SOLUTION USP 100MG/5ML- | $283.1K | 1 | 1.1% |
| 14 | AKRON EXIMS PRIVATE LIMITED GUAIFENESIN EXTENDED RELEASE TABLETS 600MGGUAIFENESIN EXTENDED RELEASE TABLETS 1200MG-14'SGUAIFENESIN EXTENDED RELEASE TABLETS 1200MG | $270.8K | 1 | 1.0% |
| 15 | LABORATE PHARMACEUTICALS INDIA LTD | $244.6K | 4 | 0.9% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Guaifenesin exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Granules India Limited | Warning Letter (February | Unknown | Unknown | Not verified | FDA issued a warning letter citing significant CGMP violations at the Gagillapur |
| Glenmark Pharmaceuticals Limited | Warning Letter (July 2025 | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP violations at the Pithampur facility. |
| Emcure Pharmaceuticals Limited | Warning Letter (August 20 | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP violations at the Hinjawadi facility. |
| Cadila Pharmaceuticals Limited | Warning Letter (2015) | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP violations. |
| Dr. Reddy's Laboratories Ltd | Warning Letter (2015) | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP violations. |
| Sun Pharmaceutical Industries Limited | Warning Letter (2016) | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP violations. |
| Ipca Laboratories Ltd | Warning Letter (2016) | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP violations. |
| Wockhardt Limited | Warning Letter (2013) | Unknown | Unknown | Not verified | FDA issued a warning letter for CGMP violations. |
TransData Nexus reviewed the regulatory standing of 8 leading Guaifenesin exporters from India. 0 hold US FDA facility approvals, 0 maintain WHO-GMP certification, and 0 are EU GMP compliant. 8 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Guaifenesin sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes to more than 40% of the country's bulk drug production. The city hosts numerous manufacturers specializing in Active Pharmaceutical Ingredients (APIs) and bulk drugs, including Guaifenesin. Companies such as SVK Laboratories Private Limited and Vasudha Pharma Chem Ltd. are prominent players in this sector. SVK Laboratories, established in 2007, focuses on producing high-quality APIs and intermediates, adhering to Good Manufacturing Practices (GMP) and international standards. Similarly, Vasudha Pharma Chem Ltd., located in Jeedimetla, Hyderabad, specializes in bulk drug manufacturing and has a significant presence in the global market.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations. Vadodara, in particular, hosts companies like Mercury Laboratories Limited, which has been a leading pharmaceutical manufacturer for over five decades, offering a diverse product portfolio across multiple therapeutic segments. Additionally, Alembic Pharmaceuticals, headquartered in Vadodara, is a significant player in the formulations sector, manufacturing and marketing a wide range of pharmaceutical products, including APIs and formulations. These companies' expertise in formulations positions them as potential partners for Guaifenesin production and export.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a crucial export gateway for India's pharmaceutical products. This cluster's well-established infrastructure and proximity to major ports facilitate efficient export operations. Companies in this region are well-equipped to handle large-scale production and distribution, making them strategic partners for exporting Guaifenesin to international markets.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh is known for its tax incentives, attracting numerous pharmaceutical companies. This zone offers a cost-effective environment for manufacturing, which can be advantageous for producing Guaifenesin at competitive prices.
5Sourcing Recommendations
- Leverage Hyderabad's API Expertise: Engage with manufacturers in Hyderabad for sourcing high-quality Guaifenesin APIs, benefiting from their established infrastructure and compliance with international standards.
- Collaborate with Formulation Specialists in Gujarat: Partner with companies in the Ahmedabad-Vadodara corridor to develop and produce Guaifenesin formulations, utilizing their extensive experience in this domain.
- Utilize Mumbai's Export Infrastructure: Establish distribution channels through the Mumbai-Thane-Raigad region to capitalize on its efficient export facilities for Guaifenesin products.
- Consider Cost Advantages in Baddi-Nalagarh: Explore manufacturing opportunities in the Baddi-Nalagarh tax incentive zone to reduce production costs for Guaifenesin, enhancing competitiveness in the global market.
By strategically engaging with these pharmaceutical clusters, TransData Nexus can optimize its supply chain for Guaifenesin, ensuring quality production and efficient distribution to meet global demand.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Guaifenesin exporters from India
GRANULES INDIA LIMITED — Granules India acquires Senn Chemicals to enhance peptide therapeutics and CDMO services
Granules India Limited announced the completion of its acquisition of Senn Chemicals, a Swiss-based company specializing in peptide synthesis and contract development and manufacturing organization (CDMO) services. This strategic move aims to strengthen Granules India's capabilities in peptide therapeutics and expand its CDMO offerings.
Impact: The acquisition is expected to diversify Granules India's product portfolio, potentially influencing its Guaifenesin export focus.
SUN PHARMACEUTICAL INDUSTRIES LIMITED — Sun Pharma acquires 60% stake in Vivaldis Health and Foods
Sun Pharmaceutical Industries Limited completed the acquisition of a 60% shareholding in Vivaldis Health and Foods Private Limited, a company specializing in animal healthcare products. This acquisition is part of Sun Pharma's strategy to diversify its product offerings and enter the animal healthcare segment.
Impact: The focus on animal healthcare may lead to a reallocation of resources, potentially affecting Guaifenesin export volumes.
SUN PHARMACEUTICAL INDUSTRIES LIMITED — Sun Pharma merges with Taro Pharmaceuticals, acquiring remaining stake
Sun Pharmaceutical Industries Limited entered into a definitive merger agreement with Taro Pharmaceuticals, acquiring the remaining stake for $347.73 million. This move aims to consolidate Sun Pharma's position in the generic pharmaceutical market.
Impact: The merger is expected to enhance Sun Pharma's manufacturing capabilities, potentially impacting Guaifenesin production and exports.
Common Questions — Guaifenesin Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which guaifenesin supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, GRANULES INDIA LIMITED leads with 181 recorded shipments worth $9.4M. ELYSIUM PHARMACEUTICALS LTD (77 shipments) and SUN PHARMACEUTICAL INDUSTRIES LIMITED (31 shipments) are also established high-volume exporters.
Q How many guaifenesin manufacturers are there in India?
India has 151 active guaifenesin exporters with a combined export market of $26.7M across 1,050 shipments to 77 countries. The top 5 suppliers hold 62.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for guaifenesin from India?
Average FOB unit price: $15.77 per unit, ranging from $0.01 to $398.12. Average shipment value: $25.4K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 151 verified Indian exporters of Guaifenesin ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,050 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 77 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,050 Verified Shipments
151 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists